TIRAT CARMEL, ISRAEL--(Nov. 29, 2010) - D. Medical Industries Ltd. (NASDAQ:DMED)(TASE:DMDC) ("D. Medical"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, today announced that Efri Argaman, D. Medical's Chief Executive Officer, will participate in the TASE-NASDAQ Biomed Conference on Monday, December 6. The conference will be held in NASDAQ's Times Square headquarters in New York City and will be launched with an opening bell ceremony featuring managers of 14 leading Israeli biomed companies, as well as the heads of NASDAQ and TASE. In addition to the opening bell ceremony, Mr. Argaman will participate in the "Cutting Edge Device Panel" at 11:45 a.m. ET.
About the TASE-NASDAQ Biomed Conference
The aim of the conference is to introduce leading NASDAQ and TASE-traded Israeli biomed companies with US investors that specialize in life sciences. Comprised primarily of small-cap biotech and medical device companies, "Biomed" is one of the most challenging and fastest growing sectors in Israel's capital market. More than 50 biomed companies trade on TASE, some of which are dually-listed on U.S. national markets as well. The conference will alert U.S. investors as to the tremendous potential engendered in the companies operating in this space. Fourteen Israeli companies will take part in the conference in various plenary presentations, professional panels and "one-on-one" meetings.
About D. Medical
D. Medical is a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery. D. Medical has developed durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient's body, using its proprietary spring-based delivery technology. D. Medical believes that its spring-based delivery mechanism is cost-effective compared to the motor and gear train mechanisms that drive competitive insulin pumps and also allows it to incorporate certain advantageous functions and design features in its insulin pumps. D. Medical has also developed an infusion set for insulin pumps and is focusing its research and development efforts on the development of next generation insulin pumps and a device that will combine a continuous glucose monitoring system and an insulin pump on the same patch. For more information, visit http://www.dmedicalindustries.com.
Forward-Looking Statements
This press release contains forward-looking statements (as defined by the Israeli Securities Law, 1968, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that involve risks and uncertainties. These statements include, forecasts, goals, uncertainties and assumptions and relate, inter alia, to D. Medical's future expectations in connection with its level of sales and cost of sales, manufacturing volumes, the cost-effectiveness of its spring-based design, target markets and timing of markets penetration. The forward-looking statements are based on D. Medical's current expectations and beliefs which are based on, among other things, its analysis of publicly available information and market research reports. All forward-looking statements are subject to certain risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward- looking statements. Such risks and uncertainties include, but are not limited to, the impact of general economic conditions, competitive products, product demand, product performance, the performance of D. Medical's contract manufacturer and distributors, regulatory trends and approvals and healthcare reform legislation. If one or more of these risks and/or uncertainties materialize, or if the underlying assumptions prove to be incorrect, D. Medical's actual results, performance or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements or results which are based upon such assumptions. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or of any of them will transpire or occur, what impact it will have on D. Medical's results of operations or financial condition. D. Medicals does not undertake to update any forward- looking statements.